Quote this publication Share Print

AVASTIN (bevacizumab), monoclonal antibody - CERVICAL CANCER

ONCOLOGY - Focus
Opinions on drugs - Posted on Oct 12 2016

Reason for request

Extension of Inclusion

Minor improvement in the treatment of persistent, recurrent or metastatic cervical cancer

  • AVASTIN has Marketing Authorisation in adults with persistent, recurrent or metastatic cervical cancer, in combination with paclitaxel and cisplatin (or in combination with paclitaxel and topotecan in those who cannot receive platinum-based treatment).
  • The addition of bevacizumab to chemotherapy has demonstrated a moderate effect on overall survival, but with reservations about the strength of the results and at the cost of accrued toxicity, especially recto-vaginal fistulas, compared to chemotherapy by carboplatin and paclitaxel.

Clinical Benefit

Substantial

-


Clinical Added Value

minor

-


Therapeutic use

-

-

 

Contact Us

Évaluation des médicaments